Exacerbation of psychosis: A case of possible varenicline-mediated effects in an intellectually disabled adult

Clinical Schizophrenia and Related Psychoses

Volumn 2, Issue 3, 2008, Pages 259-261

  Brahm, Nancy C ^a   Fast, Gary A ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^b Outpatient Psychiatry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ESCITALOPRAM; HALOPERIDOL; VARENICLINE; ZIPRASIDONE;

ADULT; AGGRESSION; ARTICLE; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CASE REPORT; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HEALTH CARE FACILITY; HUMAN; INTELLECTUAL IMPAIRMENT; LONG TERM CARE; MALE; MENTAL DEFICIENCY; MORNING DOSAGE; OBSESSIVE COMPULSIVE DISORDER; PARANOIA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOSIS; SEIZURE; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; VERBAL HOSTILITY;

EID: 55049086272     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.2.3.7     Document Type: Article

References (16)

1. Chantix (varenicline) [package insert]. New York, NY: Pfizer Labs; 2007 May.
2. Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol 2007;74(8):1182-1191.
3. Picciotto MR, Caldarone BJ, King SL, Zachariou V. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 2000;22(5):451-465.
4. Araki H, Suemaru K, Gomita Y. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn J Pharmacol 2002;88(2):133-138.
5. McEvoy JP, Schooler NR, Wilson WH. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol Bull 1991;27(2):97-101.
6. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164(8):1269.
7. Kohen I. Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164(8):1269-1270.
8. Morstad AE, Kutscher EC, Kennedy WK, Carnahan RM. Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother 2008;42(2):288-289.
9. U.S. Food and Drug Administration: MedWatch. [accessed 2008 Feb 18]. Available from:www.fda.gov/medwatch/safety/2007/safety07.htm#Chantix
10. Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med 2008;121(4 Suppl 1):S3-10.
11. Fernando WW, Wellman RJ, Difranza JR. The relationship between level of cigarette consumption and latency to the onset of retrospectively reported withdrawal symptoms. Psychopharmacology (Berl) 2006;188(3):335-342.
12. Ostacher MJ, Nierenberg AA, Perlis RH, Eidelman P, Borrelli DJ, Tran TB, et al. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry 2006;67(12):1907-1911.
13. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004;61(11):1107-1115.
14. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.
15. Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007;32(8):1715-1726.
16. Rush KS, Bowman LG, Eidman SL, Toole LM, Mortenson BP. Assessing psychopathology in individuals with developmental disabilities. Behav Modif 2004;28(5):621-637.